Currently, healthcare providers are rapidly embracing precision oncology in India to save lives. Consequently, traditional therapies are quickly giving way to highly customized treatments. For instance, next-generation sequencing (NGS) allows doctors to map a patient genomic profile within days. Therefore, oncologists can now avoid standard chemotherapy and select highly targeted drugs instead.
The Rise of Precision Oncology in India
In the past, cancer patients routinely underwent aggressive chemotherapy cycles regardless of their specific tumor biology. However, clinical understanding has shifted dramatically because every tumor possesses a unique genetic makeup. Specifically, genetic alterations trigger the growth of cancerous cells. By identifying these mutations early, doctors can match patients with targeted therapies. Indeed, targeted tablets like osimertinib have successfully restored the health of patients with advanced EGFR mutations. Additionally, these precision medicines significantly reduce painful side effects. As a result, patients experience better outcomes and enjoy a higher quality of life, which is a core focus in modern clinical oncology.
How Next-Generation Sequencing Works
Technologically, the process of genomic mapping begins with a simple biological sample like blood or tissue. Next, a sequencing machine reads millions of DNA building blocks to generate a digital map. Because of this mapping, doctors can easily identify hereditary risks and predict drug responses. Without NGS, oncologists are essentially guessing which medications might work. Furthermore, multi-gene panels can analyze hundreds of mutated genes simultaneously. Today, the cost of these tests in India has dropped substantially. Nevertheless, the cost of advanced precision medicines remains a major barrier for many low-income families.
The LuNGS Alliance and Healthcare Access
To solve the affordability issue, the Cancer Research and Statistic Foundation launched the LuNGS Alliance. Specifically, this collaborative initiative provides free NGS testing for eligible lung cancer patients across India. Supported by pharmaceutical giants and local startups, the alliance has already screened thousands of individuals. Consequently, over half of these tested patients discovered actionable mutations that guided their treatment. Meanwhile, regional hospitals in smaller towns are adopting these clinical protocols to decentralize advanced care. Ultimately, integrating NGS into government insurance schemes will make precision oncology accessible to all, a goal supported by specialized training in lung cancer management.
Frequently Asked Questions
Q1: What is the primary benefit of precision oncology in India?
Precision oncology allows doctors to customize treatment based on unique genetic mutations. Consequently, this approach avoids the broad side effects of standard chemotherapy.
Q2: How does the LuNGS Alliance help cancer patients?
The LuNGS Alliance provides free next-generation sequencing tests to eligible lung cancer patients. Therefore, patients can easily access targeted therapies without financial burden.
References
- Scanning cancer, up close & personal: A revolution is underway in cancerdiagnosis – ETHealthworld
- LuNGS Alliance launches free lung NGS biomarker testing – Express Healthcare
- Evaluating the significance of next-generation sequencing (NGS) testing in Indian patients with advanced malignancies – ASCO Publications
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.